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Abstract
Purpose With antibiotic resistance (ABR) portrayed as an increasing burden to human health, this study reviews how and to 
what extent toxicological impacts from antibiotic use are included in LCAs and supplement this with two novel approaches 
to include ABR, a consequence of antibiotic use, into the LCA framework.
Methods We review available LCA studies that deal with toxicological aspects of antibiotics to evaluate how these impacts from 
antibiotics have been characterized. Then, we present two novel approaches for including ABR-related impacts in life cycle impact 
assessments (LCIAs). The first approach characterizes the potential for ABR enrichment in the environmental compartment as a 
mid-point indicator, based on minimum selective concentrations for pathogenic bacteria. The second approach attributes human 
health impacts as an endpoint indictor, using quantitative relationships between the use of antibiotics and human well-being.
Results and discussion Our findings show that no LCA study to date have accounted for impacts related to ABR. In response, 
we show that our novel mid-point indicator approach could address this by allowing ABR impacts to be characterized for envi-
ronmental compartments. We also establish cause-effect pathways between antibiotic use, ABR, and human well-being that 
generate results which are comparable with USEtox and most endpoint impact assessment approaches for human toxicology.
Conclusions Our proposed methods show that currently overlooked impacts from ABR enrichment in the environment 
could be captured within the LCA framework as a robust characterization methodology built around the established impact 
model USEtox. Substantial amounts of currently unavailable data are, however, needed to calculate emissions of antibiotics 
into the environment, to develop minimum selective concentrations for non-pathogenic bacteria, and to quantify potential 
human health impacts from AB use.
Keywords Antibiotics · LCA · Resistance · AMR · Antimicrobials · Human health impacts · Resistance · Toxicology · 
USEtox
1 Introduction
Antibiotic (AB) substances are used for treating bacterial infec-
tions by killing or inhibiting growth of these organisms (Davies 
and Davies 2010; Kümmerer 2009). The term AB is broad and 
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envelops hundreds of different compounds, of which close to 
300 are classified as important for human medicine and are cat-
egorized into 30 + groups according to their origin and mode of 
action (World Health Organization 2019). ABs have become our 
primary tool for treating and preventing the proliferation of path-
ogenic bacterial diseases in a wide range of settings, including 
human medicine, livestock (van den Bogaard and Stobberingh 
1999), and aquaculture farms (Sapkota et al. 2008), as well as in 
agriculture to control for bacterial diseases in plants (Stockwell 
and Duffy 2012). They are the primary treatment for pneumonia, 
tuberculosis and gastrointestinal infections, diseases that histori-
cally are thought to have been responsible for 30% of all human 
deaths, but they are also essential for post-surgical care (Fair 
and Tor 2014). Inappropriate use of ABs and their environmen-
tal release may, however, result in negative consequences (in 
a concentration dependent context) in the environmental com-
partment as they can: (a) infer toxic effects on several living 
organisms (Carlsson et al. 2009) and (b) modify microbial com-
munity compositions and affect ecological functions (Costanzo 
et al. 2005; Grenni et al. 2018). Additionally, negative effects to 
humans  include: (c) indiscriminately killing both pathogenic 
and non-pathogenic bacteria, including bacterial communities 
that fill useful biological functions (Jernberg et al. 2010; Lange 
et al. 2016); (d) induce side effects in humans (Wypych and 
Marsland 2018); and (e) promote the development of antibiotic 
resistant genes (Jernberg et al. 2010; Pérez-Cobas et al. 2013).
Of the abovementioned impacts, antibiotic resistance (ABR) 
development in pathogenic bacteria is seen as the most forebod-
ing for human wellbeing, due to the central role of ABs in mod-
ern medicine (World Health Organization 2014). Bacteria can 
develop resistance to ABs either through mutations or by acqui-
sition of resistance genes from other bacteria through different 
modes of horizontal gene transfer even at low concentrations 
(i.e., ng/L to few μg/L; Cabello 2006; Grace 2015; Bengtsson-
Palme and Larsson 2016; Jutkina et al. 2018; Klein et al. 2018).
ABR genes have existed for millennia (D’costa et al. 2011), 
but the current use of tens of thousands of tonnes of ABs each 
year has resulted in substantial releases of ABs into the environ-
ment (Van Boeckel et al. 2015; Robinson et al. 2016), thereby 
generating large areas for interactions between ABs and bacteria 
which can lead selection for AB resistance genes in environ-
mental bacteria (Cabello 2006; Mathew et al. 2007; Rizzo et al. 
2013; Larsson 2014; Xiong et al. 2015; Cabello et al. 2016; 
Chuah et al. 2016; Larsson et al. 2018; Osman et al. 2018). 
There is a growing body of literature connecting ABs released 
into the environment with the development of ABR in bacterial 
communities (Heinemann 1999; Wright 2007; Larsson 2014) 
and an increased frequency of ABR genes in environmental 
compartments (Finley et al. 2013), yet the links between envi-
ronmental ABR bacteria and the impacts to human health are 
not fully understood. The collection of genes coding for ABR 
present in the environment can be viewed as a pool of available 
genetic material which can be transferred between bacteria and 
is commonly referred to as “the resistome” (D’Costa et al. 2006; 
Wright 2007; Surette and Wright 2017). Models have been 
developed for correlating anthropogenic AB emissions and the 
resistance development in the environment based on abiotic 
parameters (Amos et al. 2015), as well as relationships between 
AB use in food animal production and human exposure to ABR 
pathogens (van Bunnik and Woolhouse 2017). Nonetheless, it 
remains difficult to establish useful dose-response relationships 
between AB use and the associated impacts, since causalities 
between AB use, resistance development, and transmission are 
difficult to pinpoint (Price et al. 2015).
Despite the overwhelming human health benefits gained 
from using pharmaceuticals like ABs, it is imperative to assess 
the negative impacts from emissions of these substances to 
better improve regulation and manage impacts. Life cycle 
assessment (LCA), among other environmental frameworks, 
has been used to assess impacts related to the use of ABs. 
LCA details the environmental impacts related to a product’s 
or service’s life cycle. In LCA, human and ecosystem impacts 
from the release of chemicals are generally captured by toxico-
logical impact categories. Most of these toxicological impact 
assessment methodologies build upon available laboratory 
toxicity data and extrapolation methods assigning fate, effect, 
and exposure pathways to chemical agents. Depending upon 
scope, freshwater ecotoxicity, marine ecotoxicity, and/or can-
cer and non-cancer-related human toxicity (European Com-
mission 2010) are either estimated at an intermediary point 
in the underlying impact pathway by midpoint indicators (e.g. 
number of cancer or non-cancer disease cases in humans or 
potentially affected fraction of species in the aquatic environ-
ment; PAF  m3  kg−1), or at the end of the impact pathway as 
endpoint indicators (e.g. disability adjusted life-years (DALY) 
or potentially disappeared fraction of species to change in con-
centration (PDF  m3  kg−1) (Hauschild and Huijbregts 2015).
In this study, we first review (Sec. 3.1) how impacts from AB 
use and ABR have been characterized among published LCAs. 
We then propose two novel impact characterization models to 
capture ABR in LCA (Sec. 3.2) and discuss their respective 
strengths and weaknesses. Conclusively (Sec. 4), we summarize 
the outcomes to suggest best practices for AB use in LCA.
2  Methodology
2.1  Review of AB use in LCA literature
Relevant literature on previous LCA studies incorporating AB 
or pharmaceuticals was screened using web of science on 10 
March 2021. The search used the phrase “TS = (“LCA” OR 
“LCIA” OR “life cycle assessment” OR “life cycle analysis” 
OR “life cycle inventory assessment” OR USEtox) AND 
TS = (antimicr* OR antibio* OR pharmaceutical* OR micro-
poll*))” while delimiting the search to English-language articles 
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spanning the years 2008–2020. Search denominators and meth-
odology overview is given in the supplementary information 
(Fig. S1). The search generated 266 articles that were targeted 
for screening, of which 80 passed a title screening. Another 
37 were rejected following abstract screening. Of remaining 
43 articles read in full, 27 did not characterize ABs and were 
excluded. Thus, 16 articles are included in the review, with the 
addition of the study by Henriksson et al. (2015) that had been 
identified prior to screening, and are summarized in Table 1. 
Figures were designed using RStudio, Inc, Version 1.1.423 and 
Microsoft PowerPoint 2016.
2.2  Proposing novel approaches to include ABR 
in LCA
Potential impacts of ABs reaching the environment are sepa-
rated between toxicological impacts and resistance develop-
ment. Toxicological impacts can be captured in the current 
toxicological impact model USEtox, applying a three-step 
approach to derive characterization factors (CFs) for toxic 
substances applied in the LCA, considering fate, exposure, 
and effect data (Fantke et al. 2017; Rosenbaum et al. 2011). 
Table 1  Overview of articles reviewed that considerer AB toxicity (both human toxicity and ecotoxicity) in LCA studies
* Study acknowledged prior to review, not captured by the literature screening.
a http:// cfpub. epa. gov/ ecotox/
b http:// www. wikip harma. org
c ECOTOX Database Release 4.0, US Environmental Protection Agency, 2007
d Barceló and Petrovic, 2011; Fent et al., 2006; Isidori et al., 2005; Santos et al., 2010
e Rico et al., 2013; Rico and Van den Brink, 2014
f Dobbins et al., 2009; Iannacone and Alvariño, 2009; Ortiz de García et al., 2014; Santos et al., 2010; Terasaki et al., 2009
g https:// toxnet. nlm. nih. gov/ newto xnet/ toxli ne. htm
h www.e- toxba se. com (not accessible 2020-09-17). WWTP= wastewater treatment plants; CFs = characterization factors




Number of new 
AB CFs calcu-
lated
Ecotoxicity database (for 
antibiotics)
Munoz et al. 2008 WWTP EDIP97 and USES 2.0 Both 7 USEPA Ecotox  databasea
Munoz et al. 2009 WWTP EDIP97 and USES 2.0 Both 0 USEPA Ecotox  databasea
Hospido et al. 2010 WWTP CML 2 baseline 2000 Midpoint Muñoz et al. 2008
Stone et al. 2010 Swine farming USES-LCA 2.0 Both 0 -
Stone et al. 2011 Swine farming EcoIndicator 99 Endpoints 0 -




0 Wikipharmab and USEPA 
Ecotox database (ECO-
SAR)
Morais et al. 2013 CFs USEtox Midpoint 6 ECOTOX database 4.0c
Igos et al. 2013 WWTP EDIP2003 and USEtox Endpoint (EDIP2003), 
Midpoint (USEtox)
0 Wikipharmab and USEPA 
Ecotox database (ECO-
SAR)




4 USEtox, various 
 literatured
Henriksson et al.* 2015 Aquaculture USEtox Midpoint 24 various  literaturee, 
USEPA ECOTOX 
 databasea
Lorenzo-Toja et al. 2016 WWTP USES-LCA 2.0 Both 0 Alfonsín et al. 2014
Ortiz de Garcia et al. 2017 CFs USEtox Midpoint 7 USEPA Ecotox  databasea, 
various  literaturef
Tarpani et al. 2018 WWTP USEtox Midpoint 0 Alfonsín et al. 2014
Rahman et al. 2018 WWTP USEtox Midpoint 0 USEtox, Alfonsín et al. 
2014
Emara et al. 2018 CFs USEtox, EDIP 97, and 
USES-LCA
Both 0 USEPA Ecotox  databasea, 
 Wikipharmab, TOX-
LINE  databasef, USEtox
Li et al. 2019 WWTP USEtox Midpoint 11 RIVM e-toxBaseg, 
USEtox
Tarpani et al. 2020 WWTP USEtox Midpoint 0 Alfonsín et al. 2014
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For impacts related to resistance development, we choose to 
target: (1) ABR development in the environment as a mid-
point indicator by sourcing effect data related to concentra-
tions of ABs where resistance development can occur based 
on the risk assessment methodology developed by (Rico 
et al. 2017), and (2) human health impacts as a result from 
AB use by suggesting a linear dose-response model based on 
statistical correlation connecting AB use, resistance devel-
opment and human health impacts. This was accomplished 
by sourcing data from veterinary and medical literature 
while limiting the scope to the EU due to data scarcity.
3  Results and discussion
3.1  Findings of the review
Seventeen LCA-related articles deal with ABs, of which two 
consider indirect toxic impacts related to AB production 
and transportation (Stone et al. 2010, 2011), three calculate 
freshwater ecotoxicity CFs for ABs and use them in LCAs 
(Muñoz et al. 2008; Henriksson et al. 2015; Li et al. 2019), 
two only calculate CFs for ABs (Alfonsín et al. 2014; Ortiz 
de García et al. 2017) and eight use available CFs for ABs 
to conduct LCAs (Muñoz et al. 2009; Hospido et al. 2010; 
Igos et al. 2012, 2013; Lorenzo-Toja et al. 2016; Rahman 
et al. 2018; Tarpani and Azapagic 2018; Tarpani et al. 2020). 
Meanwhile, Morais et al. (2013) compare the uncertainty 
and variability of characterization results at various pH using 
the USEtox scientific consensus model V1.01 (Rosenbaum 
et al. 2008), and Emara et al. 2018 compare AB-related 
CFs using different impact assessment methodologies. An 
overview of reviewed articles is presented in Table 1. The 
articles were published from 2008 and onwards, the same 
year as the USEtox consensus model was developed. Of the 
thirteen studies that carried out life cycle inventory assess-
ments (LCIAs), ten evaluated wastewater treatment plant 
interventions and three animal farming. The two studies by 
Munoz et al. (2008, 2009) use both EDIP 97 (Potting and 
Hauschild 2006) and USES-LCA (Huijbregts et al. 2000) for 
LCIA, with EDIP 97 and USES-LCA 2.0 characterization 
methodologies respectively thereby characterizing impacts 
at both mid-point and endpoint. Stone et al. (2010) use ReC-
iPe 2008 (Goedkoop et al. 2013) that promotes USES-LCA 
2.0 characterization methodology for toxicological impacts. 
Meanwhile, Stone et al. 2011 use EcoIndicator99 v2.06 
(Goedkoop and Spriensma 2001) and Igos et al. (2012) 
EDIP 97 and EDIP 2003, as well as ReCiPe 2008 combined 
with USEtox. Igos et al. (2013) use EDIP2003 and ReCiPe 
2008 combined with USEtox. Hospido et al. (2010) declares 
using CLM 2 baseline 2000 for midpoint impact assessment 
(Guinée et al. 2002). Henriksson et al. (2015), Tarpani and 
Azapagic (2018), and Tarpani et al. (2020) all characterize 
freshwater ecotoxicity using USEtox V1.01, while Lorenzo-
Toja et al. (2016) characterize emissions using USES-LCA 
2.0. The two last studies, Rahman et al. (2018) and Li et al. 
(2019), perform LCIA with TRACI 2.1, where USEtox is 
the proposed toxicological characterization methodology. 
Four studies deal with more than one toxicological charac-
terization method as the focus of these studies is to evaluate 
characterization results or LCIA methodologies rather than 
performing LCAs.
Overall, the scope and methodologies vary substantially 
among studies, as do calculated CFs for ABs. Eleven stud-
ies apply USEtox methodology for impact characteriza-
tions, of which four establish CFs and seven carry out full 
LCAs. Among these, Alfonsín et al. (2014) characterize four 
ABs for both USEtox and USES-LCA. Lorenzo-Toja et al. 
(2016) utilize these USES-LCA CFs, while Tarpani and 
Azapagic (2018) and Tarpani et al. (2020) use the USEtox 
CFs from Alfonsín et al. (2014) for LCAs of wastewater 
treatment plants (WWTPs). Muñoz et al. (2008) rank the 
toxicity for 97 pollutants, create seven new CFs for anti-
biotics, and apply these in an LCA of WWTP. These CFs 
are subsequently used by Muñoz et al. (2009) and Hospido 
et al. (2010) in other LCAs of WWTPs. Henriksson et al. 
(2015) and Li et al. (2019) also generate novel CFs for ABs 
using the USEtox methodology (V1.01 and V2.0 respec-
tively) and use them for their respective LCAs. Meanwhile, 
Morais et al. (2013) investigate how pH variation influence 
USEtox fate modelling of agents and create novel CFs for six 
ABs. Ortiz de García et al. (2017) calculate CFs for seven 
additional ABs, and Emara et al. (2018) compare available 
impact assessment methodologies and CFs for ABs and 
other agents.
Of the six studies generating novel freshwater ecotoxic-
ity CFs for ABs, five present fate, exposure, and effect fac-
tors in their respective supplementary information. Two of 
these (Henriksson et al. 2015; Ortiz de García et al. 2017) 
also detail AB’s source toxicity data, but derive their effect 
factors somewhat differently. Ortiz de García et al. (2017) 
prioritized chronic toxicity data, as recommended by Fantke 
et al. (2017), while Henriksson et al. (2015) use both acute 
and chronic toxicity data.
To date, 40 antibiotic agents have been characterized for 
freshwater ecotoxicity impact with the USEtox methodol-
ogy (Fig. 1; data available in supplementary information, 
Table S1). For some ABs that were characterized more than 
once, large variations exist (e.g. 3.2E + 1 PAF  m3 per day 
and kg  emitted−1 to 1.06E + 7 PAF  m3 per day and kg emit-
ted Amoxicillin), while 24 out of 40 antibiotics only were 
characterized once.
Despite novel contributions of AB CFs using USEtox, 
only 40 of the over 300 ABs deemed critically important for 
human medicine have been characterized for freshwater eco-
toxicity (Fantke et al. 2017; World Health Organization 2019). 
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Moreover, the USEtox V2.01 database presents 23 readily 
available human health impacts for ABs, but only four of these 
have CFs for human toxicity attributed, the rest are defined as 
either “n.a” or “0”, which implies toxicity data are labelled 
as “neglected” (USEtox® organic substances database 2.01 
[built 10-July-2017]). An additional nine ABs are character-
ized for human health impacts among the reviewed studies 
(see Table 2 based on data from Emara et al. 2018). The CFs 
from Ortiz de García et al. (2017) are reported as “human 
toxicity potential – total” (an aggregation of both carcinogenic 
and non-carcinogenic impact), yet the toxicological input data 
label all of the characterized ABs as non-carcinogenic (NC) 
and they are therefore labelled as HTP-NC in Table 2.
To summarize, the use of ABs and the environmental 
release of AB residues may result in ecotoxicological impacts 
on animals and humans, changes in microbial communities 
in ecosystems and humans, and resistance development. Eco-
toxicological impacts are addressed in several LCA studies 
using different LCIA methodologies. Most of the reviewed 
studies look at freshwater ecotoxicity using USEtox, but con-
clude up to six orders of magnitude difference in CFs for some 
ABs. The cause for inconsistencies in freshwater ecotoxic-
ity CFs remains unclear since the underlying toxicity data 
used for calculating the effect factors remain unavailable. 
However, Morais et al. (2013) show that CFs are sensitive to 
differences in abiotic degradation rates as well as ecotoxico-
logical effect (EC50) data, which generally are sourced from 
different empirical experiments, as no standardized database 
for such data is available for ABs. Nonetheless, the chemi-
cal properties and experimental data on ABs that support the 
CFs remain inconsistent across literature. Greater efforts are 
therefore needed towards generating further modelling and 
experimental data for some compounds, as well as complet-
ing and harmonizing datasets of toxicological properties that 
could support effect factors to yield robust CFs.
Based on our review, we conclude that the most severe 
knowledge gaps include the evaluation of potential human 
health impacts pathways from AB use, resistance development 
in the environment, and human health impacts associated to 
ABR. Four LCA studies included impacts from ABs on human 
health, but no LCA study to date that is assessing potential 
human health impacts has tried to capture the consequences 
Fig. 1  Available CFs for AB emissions to freshwater calculated using USEtox, FETP = freshwater ecotoxicity potential. Units are presented in 
PAF  m3 day  kg−1 emitted
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of ABR. So far the only impacts considered are direct toxic-
ity without addressing ABR, which is briefly mentioned by 
Igos et al. (2012) and Emara et al. (2018). As described by 
Ashbolt et al. (2013), resistance genes which propagate in the 
environment and become a human health issue adhere to dif-
ferent pathways than ecotoxicological impacts and will there-
fore require a different impact assessment approach. Since 
ABs act as a causative agent for ABR development, spread 
of resistant bacteria can subsequently occur in the environ-
ment and be transmitted to humans. Both latter steps cannot 
be assessed through physiochemical fate models because bac-
teria are the main carriers of these resistance genes and they 
propagate through complex biological interactions. As such, 
disease transmission and subsequent impacts on human health 
are not assessed using the exposure and effect pathways cur-
rently included in the USEtox model (Eq. 1). Without relevant 
pathways to capture the extent of ABR impacts, these are pos-
sibly greatly underestimated in LCAs.
3.2  Two proposed approaches for addressing ABR 
in LCA
Since no cause-effect pathway exists for the impacts of ABR 
development in LCIA methodology, we below present two 
novel approaches that could potentially allow for ABR impacts 
to be quantified using causal relationships: (1) the use of mini-
mum selective concentration (MSC) distributions to character-
ize ABR enrichment in the environment as a mid-point impact; 
and (2) the correlation between ABs used on regional scale 
with human health impacts caused by ABR, quantified as 
DALYs per kg of AB used as an endpoint impact.
The first approach, modelling of ABR enrichment in the 
environment, uses the USEtox® methodology as a starting 
point, as it is the framework recommended by both the Soci-
ety of Environmental Toxicology and Chemistry (SETAC) 
and the Joint Research Centre (European Commission 
2010). In USEtox, Fate factors capture the physiochemical 
properties of agents and predict their estimated distribution 
in environment compartments; exposure factors calculate 
bioavailability to aquatic organisms or exposure pathways 
for humans, while effect factors benchmark the actual toxic-
ity of a compound, generally based upon laboratory studies 
(Eq. 1 describes human impact characterization and Eq. 3 
describes ecotoxicological characterization).
(1)




















Table 2  Human toxicity potential characterizations available for ABs created with the USEtox method. Units are reported as “cases per kg emit-
ted”. HTP-C: human toxicity potential: carcinogenic, HTP-NC: human toxicity potential: non carcinogenic













Metronidazole USEtox HTP-C 3.30E−07 6.52E−11 1.14E−07 2.98E-07 5.40E-07 4.81E-07
Sulfamethazine USEtox HTP-C 1.08E−07 2.31E−11 2.69E−10 1.45E-09 6.48E-08 4.48E-08
Amoxicillin Ortiz de Garcia 
2017
HTP-NC 2.11E−08 4.84E−12 2.74E−09 4.50E-09 1.75E-08 1.80E-08
Azithromycin Ortiz de Garcia 
2017
HTP-NC 6.11E−06 2.10E−08 1.76E−07 9.44E-07 4.60E-06 4.72E-06
CEFACLOR Ortiz de Garcia 
2017
HTP-NC 1.54E−08 3.17E−12 2.06E−09 3.02E-09 1.24E-08 1.28E-08
Ciprofloxacin Ortiz de Garcia 
2017
HTP-NC 1.13E−07 2.51E−11 4.46E−08 6.17E-08 1.11E-07 1.15E-07
Clarithromycin Ortiz de Garcia 
2017
HTP-NC 3.14E−07 1.21E−09 8.60E−08 1.95E-07 2.92E-07 3.01E-07
Levofloxacin Ortiz de Garcia 
2017
HTP-NC 2.51E−06 6.45E−10 1.20E−06 1.41E-06 2.17E-06 2.26E-06
Norfloxacin Ortiz de Garcia 
2017
HTP-NC 3.05E−07 6.17E−11 1.09E−07 1.28E-07 1.20E-07 1.25E-07
Sulfamethoxa-
zole
Alfonsin 2014 HTP-NC 1.58E−07 1.04E−10 1.03E−08 1.70E-08 3.24E-08 7.03E-09
Sulfamethoxa-
zole
USEtox HTP-NC 4.70E−07 1.45E−10 1.21E−07 4.35E-07 1.28E-07 7.84E-08
Trimethoprim Alfonsin 2014 HTP-NC 5.66E−07 1.54E−10 2.29E−08 3.66E-08 9.16E-08 2.39E-08
Trimethoprim USEtox HTP-NC 2.78E−06 7.67E−10 3.67E−08 3.18E-07 5.64E-07 2.84E-07
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Again, this approach is aimed at capturing toxicological 
effects of ABs, and does not prescribe how to incorporate 
ABR impacts.
3.2.1  Approach 1: characterizing ABR enrichment 
in the environment (mid‑point)
Approach 1 attempts to quantify the enrichment of resistance 
genes in environmental bacteria based on environmental fate 
models for ABs and theoretical minimum selective concen-
tration (MSC) distributions as a mid-point impact, similar 
to USEtox’s ecotoxicity impacts.
The proposed characterization model is based on the 
methodology developed by Rico et al. (2017), where MSCs 
are inferred from minimum inhibitory concentrations (MIC) 
for pathogenic bacteria obtained from the EUCAST database 
(European Committee on Antimicrobial Susceptibility Test-
ing 2020). In their study, MSCs were extrapolated from MICs 
by applying a flat extrapolation factor of 10. These extrapola-
tion factors are derived as the mean MIC/MSC ratio obtained 
in experimental studies (Gullberg et al. 2011; Liu et al. 2011), 
but refinements of this extrapolation factor should be imple-
mented as soon as further experimental or modelling data 
become available. Such improvements should account for dif-
ferences between broad-spectrum and selective antibiotics, 
considering their mode of action in bacteria.
MSC data for each antibiotic are used to fit normal distribu-
tions to the log-transformed MSC data, similarly to the spe-
cies sensitivity distribution approach used in ecotoxicological 
impact characterization (Posthuma et al. 2001). In an analogous 
manner, the MSC distributions could be used to extrapolate the 
hazardous concentration that will promote the development of 
ABR in 50% of bacteria  (HC50), which can be calculated as the 
geometric mean of the MSC data. A difference to ecotoxicity 
characterization methodology in USEtox is that  HC50 values 
are generated from the geometric mean of chronic  EC50 or 
 LC50 values (effect concentration for 50% of tested organisms 
and lethal concentration of 50% of tested organisms respec-
tively) for aquatic organisms from several trophic levels (Fantke 
et al. 2017). A chronic endpoint is preferred as the chemical fate 
and exposure calculations are performed following a steady-
state approach, so estimated environmental concentrations 
resemble chronic exposure (Guinée and Heijungs 1993). The 
use of  EC50 or  LC50 values, as opposed to a no observed effect 
concentration (NOEC) or lowest observed effect concentration 
(LOEC), is mainly supported by the statistical robustness of 
the 50% response level (Crane and Newman 2000; Larsen and 
Hauschild 2007). In the proposed approach, the MSCs approxi-
mate the chronic resistance LOEC for bacteria, which are based 
on thousands of data points compiled in the EUCAST database 
rather than on a single dose-response experiment, so a sufficient 
statistical robustness is assumed for this value as representative 
for a given bacterial taxon. Furthermore, the number of bacteria 
that is included in the EUCAST database is large (> 8) for the 
most commonly used antibiotics (Bengtsson-Palme and Lars-
son 2016). Questionable is how representative the pathogenic 
bacteria included in the EUCAST database are for bacterial 
communities in the environment. In this regard, Bengtsson-
Palme and Larsson (2016) demonstrate a weak link between 
taxonomic divergence and sensitivity to antibiotics, and the 
study by Tello et al. (2012) finds no significant difference in 
sensitivity between pathogenic bacteria that inhabit human bod-
ies exclusively and those that have been reported to also inhabit 
environmental compartments. Thus, the EUCAST database 
presents itself as a useful proxy for estimating the susceptibil-
ity of environmental communities to antibiotic pressure.
Similarly to the formula established by Jolliet et al. (2003) 
for the effect factor calculation for ecotoxicity, the effect factor 
for ABR enrichment in environmental bacteria  (EFABR) can 
be calculated as:
EFABR: ABR effect factor for a given environmental com-
partment e.g. freshwater ecosystems (PAF  m3  kg−1).
HC50: geometric mean of MSCs for bacteria (kg  m−3).
In ecotoxicity assessments, the effect factor relates to the 
change in PAF as a result of increases in contaminant concentra-
tion. In the proposed ABR enrichment assessment, this will refer 
to the change in the fraction of bacterial populations that acquire 
a significant increase of resistance genes due to a unit increase of 
AB exposure concentration. Analogous to the ecotoxicity assess-
ment, it is based on a linear extrapolation from the  HC50 down to 
 HC0 (slope of 0.5), and assumes that the acquisition of resistance 
at the community level increases with AB concentration.
Finally, the ABR characterization factor (PAF  m3 day per 
kg emitted) can be calculated as
where the fate factor describes the distribution of chemicals 
in the environment and the exposure factor describes the 
bioavailable fraction of chemicals that could cause harm to 
freshwater organisms (Fantke et al. 2017), thus utilizing the 
established modelling framework USEtox for characterizing 
distribution of ABs in the environment while only modifying 
the effect factor.
Following the methodology described above, ABR-HC50 
values were generated for 14 ABs to replace ecotoxicological 
 HC50 for USEtox input data (Table S5). The USEtox calcula-





CFABR = Fate factor
(




× Exposure factor(kg bioavailableper kg in compartment)
× Effect factor (PAF m3 per kg−1)
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interface software (available at https:// usetox. org/), selecting 
freshwater emission ecotoxicity and applying default USEtox 
setting environment. ABR enrichment characterization factors 
could subsequently be generated in harmony with USEtox 
2.1 (Table 3).
These results show that applying MSC-based  HC50 values 
for ABs enables us to derive characterizations that fit the for-
merly established LCA framework, thereby complementing 
existing freshwater ecotoxicity impacts with ABR specific 
impacts. It should be clarified that the CFs generated by 
this model serve as comparative units of impact related to 
the resistance  HC50 for bacteria at the community level, and 
not as a representation of resistance development dynamics 
following a concentration gradient, which could theoretically 
generate selection for resistance in bacteria at low concen-
trations, as well as remove resistance at high concentrations 
(e.g. killing bacteria). A strength of this approach is that all 
MIC data can be sourced from the EUCAST database, thus 
removing variations in  HC50 values due to different data 
sourcing, as highlighted for ecotoxicological data above.
Finally, a point on the ecological relevance of this 
approach should be raised. The LCA framework accounts 
for emissions under steady-state conditions (Guinée and 
Heijungs 1993), while AB emissions can be influenced 
by pharmacokinetics and environmental processes, and 
ABR development depend on the exposure level as well 
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as on the exposure duration (Ashbolt et al. 2013). This 
implies that the applicability of this model serves better 
for systems with continuous emissions than systems with 
erratic AB use (e.g., WWTPs vs. aquaculture farms), but 
may be under-representing exposure scenarios that are 
prolonged in long periods. Additionally, events related 
to proliferation of resistance genes following ABR devel-
opment, across species and exposure to humans, are not 
captured within this model. Such quantifications would be 
highly dependent on the exposure level and duration, and 
the bacteria present in the environment, which would need 
to account for more complex pathways. Connecting ABR 
enrichment in the environment to human health impacts 
(8 in Fig. 2) by incorporating other methods is currently 
being explored (Ashbolt et al. 2013; Ben et al. 2019), but 
is hampered by a lack of relevant data on how AB con-
centrations influence resistance development in human 
pathogenic bacteria and quantitative pathways describing 
environmental exposure to ABR. Hence, below we explore 
an alternative approach relating the use of ABs to human 
health impacts from ABR, which goes beyond the expla-
nation of mechanistic relationships and the quantitative 
determination of each of these pathways.
3.2.2  Approach 2: characterizing human health impacts 
for ABR (endpoint)
Our alternative approach for establishing linear dose-
response relationships between AB use and ABR conse-
quences for human well-being is conceptualized in Fig. 2. 
Ideally, one would quantify each pathway individually, but 
data scarcity currently forces us to exercise a generalized 
mass balance approach where only pathways 1, 2, 4, 6, 9, 
and 10 are aggregated into one pathway (Fig. 2). Our pro-
posed linear dose-response model assumes that any use of 
ABs will contribute to resistance development, which allows 
us to circumvent the shortcomings in data connecting envi-
ronmental ABR to human health impacts. This implies a 
loss of ecological relevance, but enables quantification 
of potential impacts from AB use at regional scales. Data 
sourced to support the approach are presented in supplemen-
tary information (Tables S2, S3, and S4 in supplementary 
information).
The relationship between AB use and ABR develop-
ment is inferred by the Joint Interagency Antimicrobial 
Fig. 2  Impact pathway overview of AB from an LCIA perspective. (1) 
AB use data is reported as DDDs per 1000 inhabitants per day (DIDs) 
in respective EU country in the ECDC database (accessed 2020-09-
19). (2) AB use data within the EU region reported as tonnes per year 
in (European Medicines Agency 2017). (3) Assessed with current fate 
models in USEtox. (4) No correlation between veterinary use of 3GC 
and resistance development in the human healthcare sector. (European 
Centre for Disease Prevention and Control (ECDC), European Food 
Safety Authority (EFSA), European Medicines Agency (EMA) 2017). 
(5) Correlation between veterinary use of 3GC and resistance develop-
ment in the food-animal sector. (European Centre for Disease Prevention 
and Control (ECDC), European Food Safety Authority (EFSA), Euro-
pean Medicines Agency (EMA) 2017). (6) Correlation between human 
consumption of 3GC and resistance development in human health care 
sector. (European Centre for Disease Prevention and Control (ECDC), 
European Food Safety Authority (EFSA), European Medicines Agency 
(EMA) 2017). (7) Proposed characterization factor in this paper, based 
on minimum inhibitory concentrations (MIC) of ABs; predictions of 
ABR development is used as a comparative endpoint. (8) Connecting 
the ABR present in the environmental compartment to AB treatment 
failure in the human and veterinary sector; no quantitative data is availa-
ble for this pathway. (9) These steps are aggregated describing the effect 
to human health from resistance developed. (10) Cassini et  al. (2019) 
assessment of treatment failure attributed to ABR can be found for the 
16 most common pathogen-resistance combinations in Europe. Loss 
of human lives and prolonged hospitalizations as an effect are assessed 
within the same report. (11) No quantitative data available on impacts 
to veterinary medicine from ABR zoonosis. (12) No quantitative data 
available. (13) Innes et  al. (2019) report an economic impact models 
from of enrofloxacin use and impacts from Campylobacter, Salmonella, 
and E. coli bacteria as externalities from AB use, which reaches US$ 
2200 per kg enrofloxacin used. The model might accommodate calcula-
tions for 3GC in the EU as well. (14) A rational for establishing nutri-
tional losses needs to be settled on. We would argue that there are highly 
variable regional differences across the world. In high-income regions, 
nutrients are easily substituted from another food source in contrast to 
low-income regions. However, antibiotic use strategies surely vary 
between small-holder animal husbandry and industrial-scale farming 
in the latter regions (no use vs. some use respectively). (15) Ecotoxico-
logical modelling according to USEtox, damage to the ecosystem from 
increased AB concentrations in the environment is characterized as 
freshwater ecotoxicity impacts. (16) Weak evidence for damage to eco-
system from ABR (Eckert et al. 2019). (17) End-point measurement of 
ecotoxicological effects, no clear ecosystem effect from ABR
◂ Table 3  ABR enrichment CFs using Approach 1 and USEtox 2.1. 
Ecotoxicological HC50 values are replaced with HC50 values based 
on geometric means of bacterial MSC distributions acquired from the 
EUCAST database (accessed 11 Nov 2020)
Antibiotic ABR enrichment charaterization 
factor [PAF  m3 day  kg−1]
Ampicillin 7.27E + 05
Amoxicillin 1.89E + 06
Cephalexin 5.75E + 05
Ciprofloxacin 5.55E + 04
Colistin 1.63E + 06
Doxycycline 3.49E + 05
Florfenicol 1.27E + 06
Kanamycin 4.43E + 05
Levofloxacin hydrate 2.39E + 07
Rifampicin 1.16E + 08
Sulfamethoxazole 1.00E + 05
Trimethoprim 9.87E + 05
Erythromycin 2.85E + 05
Roxithromycin 3.65E + 05
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Consumption and Resistance Analysis (JIACRA) report, 
which presents logistic regression models correlating use 
of 21 different ABs from five classes in human and food-
animal production in the EU and resistance development 
in five human pathogens (Salmonella spp., Campylobacter 
coli, C. jejuni, Escherichia coli, and Enterococci) (Euro-
pean Centre for Disease Prevention and Control (ECDC), 
European Food Safety Authority (EFSA), and European 
Medicines Agency (EMA) 2017). This report calculates 
odds ratios based on logistic regression analysis of AB use 
data and resistance development data to suggest statisti-
cally correlated associations between human and animal 
consumption of antibiotics, and resistance development 
in selected human pathogens. Odds ratios are explained 
by Szumilas (2010, p227) as the representation of “the 
chance that an outcome will occur given a particular expo-
sure compared to the odds of the outcome occurring in the 
absence of that exposure”.
In LCA, the endpoint of toxicological impact to humans 
is expressed as disability adjusted life years (DALY), a met-
ric that accounts for the years lost due to premature mor-
tality and productive life due to disability, and is globally 
scalable (Murray and Lopez 1994). We therefore argue that 
the common unit for ABR impacts to human health would 
be the same, given that it is a well-established concept in 
LCA’s cause-effect endpoint pathways. Data available on 
the impacts to human health have been published by Cassini 
et al. (2019), who produced an extensive report on the human 
health impacts from AB-resistant pathogens within the EU 
health care system, attributing DALYs to 16 pathogen-ABR 
combinations.
We subsequently use the impact pathway between AB use 
and DALYs to account for AB use in human and veterinary 
medicine respectively (1 and 2 in Fig. 2) in the EU, by estab-
lishing a causal relationship between AB use and ABR devel-
opment (4 and 6 in Fig. 2) together with the impacts caused 
by the subsequent failure to treat infections due to ABR (9 
and 10 in Fig. 2). We argue that the use and effect pathways 
should be parameterized according to the region of interest 
(country or continental scale), since availability and enforce-
ment of local and regional policy will arguably shape the use 
and misuse patterns of ABs at each level (Laxminarayan and 
Malani 2007; Søgaard Jørgensen et al. 2020).
To build a model for expressing DALYs as a product of 
AB use, we rely on published odds ratio data from the JIA-
CRA report (given that there is a significant correlation (e.g. 
CI does not cross 1 and p < 0.05)) to express a correlation 
coefficient between the use and resistance development for 





∂x,p,sector,reg = correlation coefficient explaining the rela-
tionship between use in the investigated sector (human or 
veterinary) and resistance development in pathogen p to 
antibiotic x in the investigated region.
ORx,sector,reg = odds ratio implying the strength of associa-
tion between use of AB x and resistance development for 
each pathogen p in the investigated sector and region.
Since odds ratio values range between 0 to infinity, we 
express this coefficient as the square root of ln OR to not 
suggest an overrepresentation of the odds for resistance 
development in a particular sector. This correlation coef-
ficient is subsequently used to imply an effect from AB use 
on resistance development, expressed as
where
ABFx,p,reg = total resistance developed in pathogen p from 
use of antibiotic x in the investigated region (resistance per 
kg  year−1).
ABUx,hum,reg = total use of antibiotic x in human health 
sector in the investigated region (kg  year−1).
∂x,p,hum,reg = correlation coefficient explaining relationship 
between human use and resistance development in pathogen 
p to antibiotic x in the investigated region.
ABUx,vet,reg = total use of antibiotic x in veterinary sector 
in the investigated region (kg  year−1).
∂x,vet,region = correlation coefficient explaining relationship 
between veterinary sector use and resistance development in 
pathogen p to antibiotic x in the investigated region.
Next, the pathways between ABF to ABR related impacts 
need to be defined (9 in Fig. 2). This step needs to be aggre-
gated with the subsequent effect; loss of lives, and prolonged 
hospitalization (10 in Fig. 2), here expressed as
DALYx,p,reg = disability adjusted life years attributed to 
resistance to AB x in pathogen p per region and year.
This gives us a mass balance approach attributing DALYs 
per kg AB used in the investigated region expressed as
To demonstrate our proposed cause-effect pathway, we 
allocate DALYs to the use of 3rd-generation cephalosporin 
(3GC) in EU, a group of beta-lactam antibiotics to which 
18 ABs belong. This class of ABs is classified as critically 
important for human medicine (World Health Organiza-
tion 2019), yet is still used within food-animal production 
to some extent (European Medicines Agency 2019). 3GC 
resistance is also among the top contributors to pathogen-
ABR related mortalities in the EU (Cassini et al. 2019). 
(5)
ABFx,p,reg = ABUx,hum,reg × x,p,hum,reg + ABUx,vet,reg × x,p,vet,reg
(Eq.6)
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Following the pathways of Fig. 2, we initially establish 
quantities of 3GC used in the EU for 2015. According to the 
ECDC Database (accessed 2020-09-17), close to 270 tonnes 
of 3GC were used for human treatment (both community 
and hospital use) in 2015 (Table S2), while the European 
Medicines Agency (2017) reports 13.9 tonnes 3GC used in 
animal husbandry that same year, totalling about 284 tonnes 
annually.
Data are available on odds ratios from the JIACRA report 
(European Centre for Disease Prevention and Control (ECDC), 
European Food Safety Authority (EFSA), European Medicines 
Agency (EMA) 2017) for human consumption of 3rd- and 
4th-generation cephalosporin antibiotics (3GC) and resistance 
development in human pathogen E. coli. Note that use of 3rd-
generation and 4th-generation cephalosporins is reported as a 
sum, but will be addressed as 3GC in this example for simplic-
ity. The reported odds ratio for this specific AB-pathogen com-
bination is 1.94 (CI 1.47–2.54, p-value < 0.001), which implies 
that odds are 94% for resistance to develop in E. coli for each 
increased defined daily dose of 3GC in the human sector. For 
the veterinary sector, however, the report shows no statistically 
significant correlation between animal consumption of 3GC 
and resistance development in the human pathogen E. coli 
(odds ratio 4.13 CI 0.78–21.08, p-value < 0.094), and ∂x,vet,region 
will hence be accounted for as “0”.
Cassini et al. (2019) report that the most critical pathogen 
resistance related–infections to human health is 3GC resistant 
Escherichia coli. This pathogen caused a median number of 
37.2 DALYs per 100,000 population reported in 2015; 191 
883 DALYs across Europe this year given a population of 
515.8 million. We input data into our model Eq. 7 according 
to Eqs. 4, 5, and 6:
which yields the following for our pathogen-resistance com-
bination E. coli infections resistant to 3GC example (Eq. 8):
To put this in perspective, we compare our 0.873 DALYs 
 kg−1 AB with the single available characterization of a 
cephalosporin-class AB, Cefaclor, a 2nd-generation ceph-
alosporin, characterized by Ortiz de García et al. (2017) 
using USEtox methodology (i.e. non-homologous method-
ology as to the case above). Ortiz de García et al. (2017) 
report that the median attributed DALYs are 5.48*10−8 
DALY per  kgemitted as non-carcinogenic impact (ranging 




lnORx,p,hum,reg + ABUx,vet,reg ×
√
lnORx,p,vet,reg
(8)0.87 DALYs per kg 3GCemitted =
191883 DALY
2.7 ∙ 105kg × 0.81406 + 1.39 ∙ 104kg × 0
from 8.62*10−12 DALY per  kgemitted to 1.98*10−8 DALY 
per  kgemitted depending on emission compartment selected).
This example shows that causal relationships are pos-
sible to infer between AB use and DALYs, but overlooks 
several important aspects and suffers from data scarcity. 
Nonetheless, we manage to establish a  CFABR for 3GC that 
associates seven orders of magnitude higher DALYs per 
kg of AB compared to a CF for a related AB which only 
considers direct toxicity impacts on humans. It should be 
noted, that 3GC is the only AB with enough data available 
to describe this pathway in a European setting currently. 
For instance, Cassini et al. (2019) do attribute DALYs to 
another pathogen resistant to 3GC, but there is no avail-
able odds ratio for this combination in the JIACRA report 
(European Centre for Disease Prevention and Control 
(ECDC), European Food Safety Authority (EFSA), Euro-
pean Medicines Agency (EMA) 2017) and characterizing 
additional ABs using this linear dose-response concept 
will require substantial data collection at regional lev-
els. However, as data are continuously being generated 
and reported, we would expect that the coverage of this 
approach could be expanded in the future (Limmathurot-
sakul et al. 2019).
Our endpoint approach is designed to characterize 
AB use in both human health and veterinary sectors, to 
account for total use of antibiotics within a region follow-
ing the One Health concept, acknowledging that ABs can 
promote ABR regardless of sector. Ideally, refining Eq. 5 
to include emissions of ABs at a production stage would 
improve the model even further, but data on the amounts 
of ABs emitted during production are largely nonexistent, 
while they are reported to be substantial in some areas 
(Larsson 2014; el Balkiny 2014). Despite that this dose-
response concept is an oversimplification of the complex 
cause-effect pathways connecting AB use, resistance 
development, dissemination, and human health impacts, 
we still had to aggregate stages in the pathway. Also, 
considering the limited data availability on ABR-related 
human impacts, only 16 pathogen-resistance combinations 
are available from Cassini et al. (2019), which limits the 
applicability of this approach. ABR frequencies and dam-
age to human health caused by economic and nutritional 
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losses from livestock mortalities are neither considered in 
our example (11–14 in Fig. 2), though Innes et al. (2019) 
have proposed a model to account for economic losses in 
a US setting which could possibly be included at further 
development of this model. Additional economic costs 
from prolonged hospitalizations due to resistant infec-
tions is neither included in our model, which is focusing 
on health impacts, but a similar approach could possibly 
be included using life cycle costing (Estevan and Schaefer 
2017). Moreover, we limit ourselves to a European setting 
where AB use could be expected to be fairly well regu-
lated, including proper reporting on and administration of 
drugs, destruction of excess drugs, full treatment cycles of 
patients and animals, and possible preliminary screenings 
for ABR genes. The current practical applicability to LCA 
of this suggested approach could be questioned since there 
is no ability to compartmentalize emissions and suggest 
impacts related to various environments. The assumptions 
made for the linear dose-response concept completely dis-
regard the beneficial aspects of AB use since many lives 
are saved each year by these pharmaceuticals and modern 
medicine relies upon functional antibiotics, but the reason-
ing of human health benefits holds true for the many other 
chemicals as well, and could be discussed with a broader 
audience. Conclusively, applying this type of simplified 
linear dose-response concept for AB use while circum-
venting stochastic dynamics of ABR development and the 
contribution of resistance from the environmental com-
partment will imply statistical inference without causality.
Since there is no available methodology to extrapolate how 
environmental ABR impacts human health in an LCA con-
text, we had to create two separate pathways, one prospective 
method which looks at the onset of ABR in environmental bac-
teria using the established characterization model USEtox, and 
a second retrospective method based on statistical correlations 
between AB use and human health impacts. Since these mod-
els are based on different assumptions with little commonality, 
they express different strengths and shortcomings that need 
to be considered before implementation. We view these two 
novel AB characterization methodologies as steppingstones to 
further refinements and discussions on the holistic assessment 
of ABs and resistance development in LCA.
4  Conclusions
ABs have been assumed to contribute to ecotoxic-
ity and human toxicity in seventeen LCAs, but the lat-
ter impact category is sparsely characterized. Moreover, 
ABR impacts as a consequence of AB use have not yet 
been accounted for in LCA, which suggests that the full 
impacts of AB use in LCAs are severely underestimated. 
In response, we present two approaches that acknowl-
edge these impacts and that can be readily included in 
existing impact assessment models to generate characteri-
zation factors for ABR enrichment in the environment at 
a mid-point level, and a correlation between AB use and 
DALYs for endpoint impacts. The mid-point characteri-
zation approach for ABR enrichment in the environment 
provides a robust comparative model for assessing AB use 
or removal from wastewater, agriculture, or industrial pro-
cesses. Further development of this methodology would 
benefit from refining the current MIC to MSC extrapola-
tions since a fair amount of AB MIC data are available. For 
the endpoint approach, we use 3GC as an example to prove 
the concept of our theory, but few causal relationships and 
data limitations challenge the practical usefulness of this 
approach at present. We would therefore recommend cau-
tion when interpreting human health impacts from ABs in 
LCA studies until more holistic methodologies and bet-
ter data become available. Future LCAs including ABs 
should ideally adopt a One Health approach and could 
benefit from complementary environmental risk assess-
ments, allowing for the dynamics of AB use and emission 
in all relevant sectors to be accounted for.
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